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Cell-based therapies represent a promising alternative to orthotopic liver transplantation. However, therapeutic effects
are limited by low cell engraftment rates. We recently introduced a technique creating human hepatocyte spheroids for
potential therapeutic application. The aim of this study was to evaluate whether these spheroids are suitable for
engraftment in diseased liver tissues. Intrasplenic spheroid transplantation into immunodeficient uPA/SCID/beigemice
wasperformed.Hepatocyte transduction ability prior to transplantationwas tested by lentiviral labelingusing red-green-
blue (RGB) marking. Eight weeks after transplantation, animals were sacrificed and livers were analyzed by immu-
nohistochemistry and immunofluorescence. To investigate human hepatocyte-specific gene expression profiles inmice,
quantitative real-time-PCRwas applied. Human albumin and alpha-1-antitrypsin concentrations in mouse serumwere
quantified to assess the levels of human chimerism. Precultured human hepatocytes reestablished their physiological
liver tissue architecture and function upon transplantation in mice. Positive immunohistochemical labeling of the
proliferating cell nuclear antigen revealed that human hepatocytes retained their in vivo proliferation capacity. Ex-
pressionprofiles of humangenes analyzed in chimericmouse livers resembled levels determined in native human tissue.
Extensive vascularization of human cell clusters was detected by demonstration of von Willebrand factor activity. To
model gene therapy approaches, lentiviral transduction was performed ex vivo and fluorescent microscopic imaging
revealed maintenance of RGB marking in vivo. Altogether, this is the first report demonstrating that cultured and
retroviral transduced human hepatocyte spheroids are able to engraft and maintain their regenerative potential in vivo.
Introduction
Therapeutic application of primary human hepato-cytes as an alternative to liver transplantation repre-
sents a promising model for patients with liver-based
metabolic disorders or hepatic failure. Data from small
animal models indicate that successful hepatocyte trans-
plantation of 5–10% of liver cell mass is required to correct
inherited metabolic diseases.1 For liver regeneration in
patients with fulminant hepatic failure it has been esti-
mated that 1–5% of liver mass will be needed.2 Further-
more, hepatocyte transplantation has been suggested as
bridging therapy until a suitable donor organ becomes
available in fulminant liver failure or in patients with
metabolic disorders.3,4 The excellent regenerative potential
of the liver also supports the hope for native liver regen-
eration after clinical liver cell transplantation.5
Nevertheless, intraportal hepatocyte transplantation using
freshly isolated cells has not yet been routinely established
in clinical practice, but first clinical case reports demon-
strated principle feasibility and safety of this technique.6–9
Relatively small cell numbers could theoretically restore
liver function in vivo. So far, the success of intraportal he-
patocyte transplantation using single-cell suspensions has
been limited by the low rates of cell engraftment achieved
and marginal beneficial effects obtained,10 thus indicating
that the development of new technologies enabling hepa-
tocyte regeneration before transplantation may be required.
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Another problem in cell transplantation includes the lack
of storing opportunities for highly differentiated human
hepatocytes due to the rapid loss of hepatocyte functions
that is commonly observed under the currently used two-
dimensional (2D) culture conditions.11 Moreover, previous
studies showed that cryopreserved hepatocytes are fre-
quently not suitable for clinical cell transplantation due to
their significantly reduced cell attachment.12
Hepatocyte morphology and function have been shown to
be better maintained by tissue engineering methods using
hepatocyte culture on three-dimensional (3D) scaffolds.13–19
Alginate is a naturally occurring anionic biopolymer typically
obtained from brown seaweed. It has been extensively in-
vestigated and used for a broad range of tissue engineering
applications due to its biocompatibility, low toxicity, and
relatively low cost.20 Another advantage is that scaffolds
based on alginate can be dissolved without any cytotoxicity to
enable harvesting of cultured cells. We previously created
functional human hepatocyte spheroids by preculturing the
cells for 7 days on alginate bioscaffolds.19 We propose that
this technique provide a means to enhance cell engraftment
rates in the recipient liver by applying spheroid transplanta-
tion after scaffold dissolving as an alternative to single-cell
application. Moreover, hepatocyte preculturing may offer
opportunities for cell analysis, therapeutic gene manipula-
tion, or simply to bridge the availability of highly differen-
tiated hepatocytes from a donor liver if the recipient is
temporary not available. To assess some of these possibilities,
we now performed transplantation of precultured spheroids
into uPA/SCID/beige (USB) mice. In this mouse model of
liver regeneration, overexpression of the uPA transgene leads
to liver damage, which turns into a cell growth advantage of
xenotransplanted hepatocytes, while the SCID beige muta-
tion ensures the necessary immunological tolerance.21–23
In brief, the aim of our experiments was to determine
whether ex vivo engineered and culture-derived human he-
patocyte spheroids are suitable to reconstitute the diseased
liver of recipient animals.
Materials and Methods
Full methods are available in the Supplementary Data
section (Supplementary Data are available online at
www.liebertpub.com/tea).
Bioscaffolds for 3D cell culture
Alginate bioscaffolds in 24-well plates (AlgiMatrix 3D
Culture System, Cat. No. 12684–023) were purchased from In-
vitrogen (Carlsbad, CA). Directly before use, the scaffolds were
transferred to a 24-well culture plate (Corning, Lowell, MA).
Isolation of primary human hepatocytes
The study was approved by the Ethical Review Committee
of the Rheinische Friedrich-Wilhelms-Universita¨t Bonn
(021/12) and the committee of the A¨rztekammer Hamburg
(WF-021/11). Handling of the humanmaterial was performed
in accordance with national guidelines, the 1975 Declaration
of Helsinki, and after informed consent in writing from each
patient’s parents. Primary human hepatocytes were isolated
from the liver tissue of five children. The first four children
underwent liver transplantation due to metabolic diseases or
hepatoblastoma, and hepatocytes from these donors were
isolated from the explanted livers. One patient underwent size
reduction due to relative liver hypertrophy in the context of
omphalocele. Hepatocytes from this donor were isolated from
the resected liver tissue. Table 1 displays the donor charac-
teristics in details. Samples of organ tissues were flash frozen
and stored at -80C before starting the cell isolation proce-
dure. Right after explantation/resection hepatocytes were
isolated as described earlier.19 Samples of cells were flash
frozen in liquid nitrogen immediately after the isolation
procedure and stored at -80C for further analysis.
Cell seeding and culture conditions
The alginate bioscaffolds were seeded with 200mL cell sus-
pension per scaffold containing 1·106 hepatocytes. Cells were
cultured in 400mL supplemented William’s Medium E without
L-Glutamine (Invitrogen) perwell as described previously.19Cell
culture medium was furthermore supplemented from day 3 on-
ward with 2%DMSO, 2mM 3-methylcholanthrene, and 10mM
dexamethasone (Sigma Aldrich, St. Louis, MO) for cytochrome
P450 (CYP) isoenzyme induction.11 The scaffolds were incu-
bated in a humidified atmosphere of 5%CO2 and 95%air at 37C
during 7 days. Culture medium was changed every 24h.
RGB marking and lentiviral transduction
In experiment C hepatocyte transduction ability was tes-
ted before transplantation using a principle named red-
green-blue (RGB) marking.24 Lentiviral Gene Ontology
(LeGO) vectors each expressing one of the three fluorescent
proteins (mCherry = red, Venus = green, Cerulean = blue)
were designed as described.24,25
Target cells were simultaneously transduced 24 h pre-
transplant with a multiplicity of infection (MOI) of 20 for each
fluorescent protein achieving an overallMOI of 60 (givenMOIs
are calculated relatively to the titration cell line HEK-293T).
Spheroid harvesting and transplantation in USB mice
After 7 days of preculture the bioscaffolds were trans-
ferred to a centrifugation tube and dissolved as previously
Table 1. Donor and Isolation Characteristics
Patient Donor age/sex Donor diagnosis Time of cold ischemia (hours) Cell viability (%)
A 18 years/m Primary Oxalosis 48 95
B 4 months/m Maple syrup urine disease 16 75
C 2 months/m Maple syrup urine disease 7 99
D 2 years/m Hepatoblastoma 21 70
E 14 days/w Size reduction due to relative
liver hypertrophy by omphalocele
18 98
Average viability – Standard deviation (%) 87.4 – 12.3
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described.19 In experiment C, applying RGB marking,
spheroids were analyzed by fluorescence microscopy before
transplantation to estimate transduction efficiency.
USB mice were originally generated by crossing Alb-uPA
mice (strain TgN(Alb1Plau)144Bri; The Jackson Labora-
tory, Bar Harbor, ME) with homozygous SCID/beige mice
(strain C.b-17/GbmsTac-SCID/bgN7; Taconic Farms, New
York, NY). USB mice were housed and maintained under
specific pathogen-free conditions in accordance with insti-
tutional guidelines under approved protocols. The presence
of the urokinase-type plasminogen activator (uPA) trans-
gene and maintenance of the severe combined immunode-
ficiency (SCID/beige) phenotype were determined as
reported.26 All animal experiments were conducted in ac-
cordance with the European Communities Council Directive
(86/EEC), and were approved by the city of Hamburg,
Germany (47/11, 15/12, 66/12).
Three-week-old mice were anesthetized with isoflurane
and injected intrasplenically with 1 · 106 precultured human
hepatocytes forming spheroids. After 8 weeks, animals were
sacrificed, livers and spleens were explanted, and snap fro-
zen in liquid nitrogen for RNA isolation. Livers from mice
transplanted with RGB-marked human hepatocytes
underwent treatment as described earlier.24
Human albumin and alpha-1-antitrypsin assays
To verify repopulation of mouse livers with human he-
patocytes, human albumin and alpha-1-antitrypsin (A1A)
concentration in mouse serum was measured 8 weeks after
transplantation by enzyme-linked immunosorbent assay
(ELISA) using a human albumin or human A1A quantifi-
cation kit (ICL, Newberg, OR), respectively.
Immunohistochemical analysis
To proof the presence of zonation immunohistochemical
labeling of arginase 1 (ARG1) and glutamine synthetase
(GLUL) was performed applying a periportal or perivenous
marker, respectively. Furthermore, immunohistochemical
labeling of the proliferating cell nuclear antigen (PCNA)
and A1A was performed. To display human hepatocyte
clusters in mouse livers cryosections (6mm) were im-
munohistochemically stained with a mouse monoclonal
antibody against human cytokeratin 18 (humCK18). All
antibodies used for immunohistochemical stainings are lis-
ted in Supplementary Table S1. For visualization the En-
Vision G2 double-staining system (Dako) was applied in
addition to hematoxylin background staining. All sections
were analyzed by light microscopy.
Immunofluorescence analysis
Human-specific cytoskeletal marker cytokeratin 18
(humCK18) was stained as described19 to visualize human
clusters in mouse livers and spleens. Furthermore, mor-
phological characteristics and activity of hepatocyte-specific
factors in livers were demonstrated as detailed in Supple-
mentary Table S2. For the detection of bile canaliculi the
sections were incubated with Alexa 488-labeled Phalloidin
(Invitrogen; 1:50, 1 h) to stain actin filaments in green.
Hoechst 33258 (Invitrogen) was used as counterstaining for
viable cell nuclei (1:20,000, 1min).
All sections were visualized by fluorescence microscopy.
RNA isolation and reverse transcription PCR
RNA isolation and reverse transcription were performed
in three of the five experiments (patient A, B, and C). After
harvesting at day 1 and 7 of cell culture the scaffolds
were dissolved. The released cells/spheroids were incorpo-
rated into 350 mL RLT-buffer (Qiagen, Hamburg, Germany)
and 3.5 mL b-mercaptoethanol (Sigma-Aldrich). The same
process was performed with the native human tissue before
cell isolation, the cells frozen directly after isolation and the
humanized mouse livers after explantation. The total RNA
was extracted from the lysate using RNeasy Mini Kit
(Qiagen). For cDNA synthesis the First Strand cDNA
Synthesis Kit for reverse transcription PCR (AMV) from
Roche was used. The first strand cDNA synthesis reaction
was performed under the following conditions: 25C for
10min, 42C for 60min, 99C for 5min, and cooling to 4C.
Real-time PCR
Real-time PCR amplification was deployed to quantify
the gene expression of liver cell-specific factors applying
the QuantiTect SYBR Green PCR Kit (Qiagen) in combina-
tion with human gene-specific QuantiTect Primer Assays
(Qiagen). The details for the target genes are listed in Sup-
plementary Table S3. Primers were tested for their human
specificity before use. The expression of hepatocyte-specific
factors was quantified using the comparative CT method.
Human Beta-actin (ACTB) was used as internal control. All
reactions consisted of 12.5 mL 2· QuantiTect SYBR Green
PCR Master Mix, 2.5 mL 10· QuantiTect Primer Assay, and
1 mL cDNA as PCR template. The reactions were performed
applying the StepOnePlus Real-time PCR System (Applied
Biosystems, Foster City, CA). The cycling conditions were as
follows: 95C for 10min followed by 45 cycles with 94C for
15 s, 60C for 30 s, and 72C for 30 s. Melting curve analysis
was performed routinely to verify the specificity of real-time
PCR products. To further detect nonspecific amplifications
real-time PCR products were transferred to a 2% agarose gel
running in TRIS borate EDTA buffer at 80V/400 mA for
50min.
Statistical analysis
Unpaired Student’s t-test was used to compare the results
of quantitative real-time PCR measurements. p < 0.05 was
accepted as significant whereas p < 0.01 was considered as
highly significant.
Results
Isolation and maintenance of primary human
hepatocytes in 3D cell culture
A mean cell viability of 87.4% – 12.3% (n= 5 isolations)
was determined by Trypan blue test immediately after he-
patocyte isolation (Table 1). Notably, isolation from a donor
organ with 48 h of cold ischemia (Patient A) had an excellent
outcome of 95% cell viability. Cell viabilities obtained from
livers of metabolically disordered children were comparable
with those achieved in hepatoblastoma or liver resection,
respectively. All experimental steps involving liver cell iso-
lation, in vitro spheroid formation, isolation, and transplan-
tation in mice are summarized and displayed in Figure 1. In
744 BIERWOLF ET AL.
regard to the spheroid formation and as previously reported19
hepatocyte aggregation within the pores of the scaffold was
already observed after 24 h in 3D culture. From day 3 onward
formation of spheroids was observed, which reached their
maximum diameter (about 100–150mm) at day 7.
Human hepatocyte spheroids repopulate mouse livers
after 7 days of preculture
Primary human hepatocyte spheroids were transplanted
into mice after 7 days.19 Successful engraftment and in vivo
expansion of precultured human hepatocytes could be
demonstrated in 11/33 animals that had been sacrificed 8
weeks after spheroid transplantation by visualization of
humCK18. As shown in Figures 1 and 2, immunohisto-
chemical staining of humCK18 revealed that human hepa-
tocyte spheroids successfully reconstituted the diseased
mouse liver parenchyma, since a uniform distribution of
human clusters with a diameter between 200 and 3000 mm
was detected in all liver lobes. Human liver tissue was es-
timated to replace up to 30% of mouse liver tissue. No signs
of tumor development, fibrosis, or cirrhosis were detected in
FIG. 1. Experimental design. Human hepatocytes isolated from donor livers were cultured on alginate scaffolds. After
7 days of preculture hepatocytes forming spheroids were harvested and transplanted into uPA/SCID/beige mice to inves-
tigate engraftment. A representative section of a humanized mouse liver 8 weeks after spheroid transplantation is shown.
HumCK18 immunohistochemical staining (red) demonstrates human hepatocyte clusters in mouse livers, hematoxylin was
used as background staining (blue). Color images available online at www.liebertpub.com/tea
FIG. 2. Results of transmission light microscopy. (A) HumCK18 immunohistochemistry (red) for detection of human
clusters was applied together with alpha-1-antitrypsin staining (A1A, brown). Hematoxylin was used as background staining
(blue). Nearly all human hepatocytes displayed positive signal for A1A demonstrating the presence of highly functional
hepatocytes in human clusters. (B) PCNA (brown) immunohistochemistry was used to demonstrate proliferation activity in
combination with humCK18 (red) staining for detection of human clusters in mouse livers. Hematoxylin was applied as
background staining (blue). Almost all human hepatocytes stained positive for PCNA indicating strong proliferative activity.
A1A, alpha-1-antitrypsin; PCNA, proliferating cell nuclear antigen. Color images available online at www.liebertpub.com/tea
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mouse livers. HumCK18 staining of spleens revealed no
evidence of remaining human hepatocytes (data not shown).
Precultured human hepatocytes retain their in vivo
proliferation capacity and differentiation status in vivo
To assess the presence of human hepatocyte-specific
functions in mouse livers, we determined human serum al-
bumin (HSA) concentration in mice 8 weeks after spheroid
transplantation. Median HSA concentration was 576 mg/mL
but varied between 3.5 to 1396 mg/mL in accordance with
the repopulation rates achieved (Table 2). A1A production
was demonstrated in human hepatocyte clusters as displayed
in Figure 2A. We furthermore confirmed our histological
results using a human A1A ELISA test. Values ranged be-
tween 0.6 to 498mg/mL with a median human A1A con-
centration of 156mg/mL (Table 2).
Loss of proliferative capacity is commonly observed
during hepatocyte cell culture. PCNA staining of humanized
mouse livers revealed that despite 7 days in culture human
hepatocytes retained their proliferation capacity in vivo.
Interestingly, many hepatocytes in the border area of human
clusters stained positive for PCNA indicating that prolifer-
ation activity was still ongoing 8 weeks after spheroid
transplantation (Fig. 2B).
The human cytoskeletal marker CK18 was applied to
distinguish between human and mouse hepatic tissue
(Fig. 3A). Visualization of hepatocyte nuclear factor 4










A 5 1 497 59.3
B 5 2 1312 498
1396 485
C 5 4 Not analyzed Not analyzed
D 6 1 782 47.7
E 12 3 27.9 3.2
12.0 0.8
3.5 0.6
Total animals 33 11
Successful human hepatocyte engraftment after spheroid transplantation could be demonstrated in 11/33 animals by visualization of the
human cytoskeletal marker cytokeratin 18 (humCK18).
FIG. 3. Immunofluorescence staining of humanized mouse livers 8 weeks after spheroid transplantation. (A) HumCK18
(green) staining was performed to distinguish between human and mouse hepatic tissue. Hoechst 33258 (blue) was used as
background staining. Successful human hepatocyte engraftment could be achieved in 11/33 transplanted animals. Human
hepatocytes in mouse livers revealed excellent viability with well-organized physiological cytoskeletal network. In the left
picture the border between human and mouse liver tissue is marked by a white line. Numerous macrophages (white arrows)
were noticed as typically observed in young mice in this animal model. (B) Double staining of hepatocyte-specific
transcription factor HNF-4 (red) and humCK18 (green). Positive nuclear staining of HNF-4 indicates highly preserved
hepatocyte differentiation. HNF-4, hepatocyte nuclear factor 4. Color images available online at www.liebertpub.com/tea
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FIG. 4. Immunofluorescence staining of hepatocyte-specific factors in chimeric livers 8 weeks after spheroid transplan-
tation. (A) For detection of actin filaments in bile canaliculi Alexa 488-labeled Phalloidin (green) was used. Re-formation of
bile canaliculi between bordering hepatocytes was observed displaying the physiological micro-structure of the liver. A cross-
sectioned bile canaliculus is marked by the white arrow. (B) Von Willebrand factor (vWF, red) labeling was performed to
demonstrate vascularization of human tissue inmouse livers. Large vessels (white arrow) ofmouse origin spread out into human
clusters providing nutritional and oxygen supply alongwithwaste removal. (C) Immunofluorescent staining of cytochrome P450
(CYP, red) revealed positive human hepatocytes in mouse livers indicating the ability to metabolize toxic substances (white
arrow). (D)Multidrug resistance-associated protein 2 (MRP2) is predominantly found in the canalicular membrane of polarized
hepatocytes. In our mouse model MRP2 (red) is visible as stripe between adjacent hepatocyes (white arrow) as also observed in
physiological hepatic tissue. (E) Immunofluorescent staining of the tight junction protein zonula occludens protein 1 (ZO-1, red)
was performed to demonstrate bipolar hepatocyte configuration in human clusters with apical and basolateral membrane. In our
chimeric livers, tight junctions were detected not only between hepatocytes of one species but also between mouse and human
hepatocytes (white arrow). (F) Immunofluorescent staining of the gap junction protein Connexin 32 (Co32, red) revealed positive
signaling not only between human hepatocytes, but also between hepatocytes of the two different species (white arrow) indicating
highly differentiated hepatocyte interaction, enabling cell-to-cell communication. HumCK18 (green/red) labelingwas applied in
all of our immunofluorescent stainings to distinguish between human andmouse hepatic tissue. Hoechst 33258 (blue) was used as
counterstaining for viable cell nuclei. Color images available online at www.liebertpub.com/tea
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(HNF-4) alpha was performed to observe the state of cell
differentiation. Nearly all human hepatocytes displayed
positive nuclear transcription factor HNF-4, indicating that
hepatocyte differentiation is highly retained in transplanted
cells (Fig. 3B).
Phalloidin staining was established for detection of actin
filaments that are localized in bile canaliculi. Bile canaliculi
network embracing mouse and human hepatocytes was de-
tected in chimeric livers displaying liver tissue-specific
microstructure (Fig. 4A).
Von Willebrand factor (vWF) activity demonstrated
vascularization of human clusters in mouse livers. Small
capillaries, and large blood vessels, were detected both
within human clusters and spread out from mouse liver areas
into human clusters (Fig. 4B). As a result of species-specific
CD31 staining it could be clarified that the vessels were of
mouse origin (pictures not shown).
As displayed in Figure 4C, positive CYP2E1 staining of
human hepatocytes in mouse livers indicated that pre-
cultured hepatocytes maintained their capability to metab-
olize potentially toxic compounds.
Multidrug resistance-associated protein 2 (MRP2) is
predominantly found in the canalicular membrane of po-
larized hepatocytes and mediates biliary excretion of en-
dogenous or exogenous substances.27 Analysis of MRP2
localization in human clusters within the chimeric livers
revealed not only positive staining but also a distribution
resembling normal human liver tissues (Fig. 4D).
Zonula occludens protein 1 (ZO-1) is a marker for tight
junctions that indicates bile canaliculi formation and bipolar
hepatocyte configuration in liver tissue.28,29 In our chimeric
livers tight junctions were detected not only between he-
patocytes of one species but also between mouse and human
hepatocytes as displayed in Figure 4E. Moreover, positive
staining of the gap junction protein connexin 32 (Co32)
indicated intercellular communication.30 Positive staining
for this marker was also observed both between human
hepatocytes and between hepatocytes of the two different
species (Fig. 4F).
Altogether, no encapsulation and no strict border between
the hepatocytes of the different species were observed, in-
dicating excellent integration of human hepatocyte spher-
oids in mouse liver parenchyma. Moreover, humCK18
visualization and Hoechst 33258 nuclear counterstaining
revealed that human hepatocytes in mouse livers were well
organized with physiological cytoskeletal network (Figs. 3
and 4). Our results with ARG1/GLUL staining show that
there was no structural heterogeneity relative to hepatocyte
location in human clusters. Nearly all human hepatocytes in
mouse livers stained slightly positive for both markers
(Supplementary Figs. S2 and S3).
To investigate the gene expression profile of human he-
patocytes in chimeric mouse livers, quantitative real-time
PCR measurements were performed. Figure 5 summarizes
results of liver-specific human genes obtained in mice in
comparison with native human tissue, freshly isolated hu-
man hepatocytes, and cultured hepatocytes. Nearly constant
Alb mRNA expression was observed in native tissue and
freshly isolated cells, respectively, whereas Alb gene ex-
pression in cultured cells decreased as expected.
CYP1A2 expression levels decreased at the beginning of
the cell culture and increased thereafter as a result of CYP
induction. CYP3A4 induction was already low in the basic
tissue and below detection limit in the cultured cells. Copy
numbers of transferrin and phase II enzyme glutathione S-
transferase (GSTA1) decreased after cell isolation but
FIG. 5. Results of real-time PCR.Gene expression pattern of human hepatocytes in native tissue before cell isolation compared
to freshly isolated cells (three experiments), cells on alginate scaffolds after 1 and 7 days of culture (n= 5/t, three experiments) and
in vivo expressionofhumanhepatocytes inmouse livers (n= 7, three experiments).ACTBwasusedas internal control.The values
are expressed as mean–SD. In vivo expression levels of all analyzed human genes in mice were nearly identical compared to
expression levels in native human tissue before cell isolation. Statistical analysis revealedno significant differences between these
two groups. CYP, cytochrome P450; GSTA1, glutathione S- transferase; n.s., not significant; TF, transferrin. Color images
available online at www.liebertpub.com/tea
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remained constant during the entire culture period. Re-
markably, in vivo expression levels of all human genes an-
alyzed appeared almost identical in chimeric mouse livers
compared to expression levels determined in native human
liver tissue before cell isolation. Statistical analysis revealed
no significant differences between these two groups. Melt-
ing curve analysis resulted in a single-specific peak for each
amplified product demonstrating the specificity of real-time
PCR (Supplementary Fig. S1A). To further validate real-
time PCRs products were separated on 2% agarose gels.
Only single specific bands were observed for each PCR
indicating the absence of nonspecific amplification (Sup-
plementary Fig. S1B).
Efficient engraftment of RGB-marked cells
Simultaneous hepatocyte transduction with three LeGO
vectors encoding red, green, or blue fluorescent proteins was
performed in experiment C after 6 days of preculture. Fluor-
escent imaging obtained right before spheroid transplantation
into mice confirmed effective multi-color labeling of human
hepatocytes. The three basic colors, but also numerous hues
resulting from their mixtures can be distinguished (Fig. 6A).
Fluorescent microscopic imaging of explanted livers dem-
onstrated stable RGB marking of human hepatocyte clusters
that originated upon multiple rounds of cell divisions
(Figs. 6B–D). As previously reported,24 we predominantly
FIG. 6. Results of in vitro lentiviral transduction. (A) Fluorescent imaging right before spheroid transplantation revealed
high-rate lentiviral transduction of primary hepatocytes with the three LeGO vectors encoding mCherry (red), Venus (green)
and Cerulean (blue). Simultaneous presence of these three basic colors in individual cells resulted in efficient RGB marking
(merged image). (B–D) Fluorescent microscopic imaging of explanted livers showed stable in vivo red, green, and blue
labeling in human clusters upon multiple rounds of cell divisions. (E) Just a few human clusters remained negative for RGB
marking. LeGO, Lentiviral Gene Ontology; RGB, red-green-blue. Color images available online at www.liebertpub.com/tea
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found clusters of human hepatocytes displaying the same
RGB marking pattern, revealing monoclonal expansion of
individual human hepatocytes that successfully engrafted the
mouse livers at a given spot. Since the overall transduction
rates were below 100% as expected, a few human clusters
remained negative for RGB marking (Fig. 6E).
Discussion
Liver transplantation is the preferred therapy for patients
with end-stage liver diseases or liver-based inherited meta-
bolic disorders. Nevertheless, due to organ shortage alter-
native treatments such as hepatocyte transplantation have
been developed and clinically applied in selected cases.6–9
Unfortunately, the success of this treatment has been limited
by low cell engraftment rates and the restricted sources of
human hepatocytes. We previously showed that hepatocytes
obtained from children with inherited metabolic disorders
form highly differentiated human hepatocyte spheroids that
preserved metabolic activities even after 7 days of culture.19
Herewith, we used the well-established uPA mouse model
of liver regeneration to assess the regenerative potential of
such precultured spheroids in vivo.
The levels of human liver chimerism commonly achieved
in uPA mice are known to variate strongly among trans-
planted animals and depend both on the different rates of
initially engrafted hepatocytes and on the capacities of these
cells to expand in vivo. Although we observed a large but
not unusual variety in human HSA and A1A concentrations
and repopulation rates among transplanted mice, large hu-
man hepatocyte clusters were determined in mice that had
been successfully engrafted with spheroid-derived primary
human hepatocytes.
It is known that in vitro loss of proliferative capacity is
one of the most restricting problems during hepatocyte
culture. As determined by the presence of large human he-
patocyte clusters and PCNA staining in transplanted mice,
we demonstrated that the precultured hepatocytes could
regain their proliferation capacity in vivo.
Extensive histological examinations were performed to
confirm physiological morphology of human hepatocyte
clusters in mouse livers. HNF-4 is one of the major liver-
specific transcription factors and participates in the regulation
of several genes involved in liver-derived metabolic path-
ways.31 In our model almost all human hepatocytes revealed
positive staining 8 weeks after transplantation, indicating the
maintenance of highly differentiated human hepatocytes
forming human liver tissue within the mouse livers.
ZO-1 is known to be located in the intercellular tight
junctions indicating maintenance of cell polarity. Positive
staining of ZO-1 together with actin filament labeling by
phalloidin revealed re-formation of bile canaliculi and bi-
polar configuration between adjacent human hepatocytes in
mouse livers. Notably, tight junctions were not only de-
tected between human hepatocytes but also between mouse
and human hepatocytes. These findings are highly relevant,
since isolated hepatocytes lose their polarized structure after
dissociation from liver tissue.28
To prove in vivo angiogenesis of human clusters vWF
activity was analyzed. We observed both small capillaries
and large vessels within human hepatocyte clusters provid-
ing nutritional and oxygen supply and waste removal.
One of the most important hepatocyte functions is their
ability to metabolize drugs and toxic substances. We stained
CYP2E1 as an important member of the CYP gene family
enabling, for instance, ethanol and paracetamol detoxifica-
tion in humans.32 The presence of positive human hepato-
cytes 8 weeks after spheroid transplantation suggests
maintenance of detoxification capacity.
Moreover, the localization of MRP2 in the apical mem-
brane of polarized epithelia favors a particular role of this
isoform in detoxification pathway.33 The presence of MRP2
with physiological distribution in our humanized livers in-
dicates that efficient terminal excretion of conjugated drug
metabolism products via bilious flow is possible.
In physiological liver tissue, there is a strong functional in-
teraction between neighboring cells. It was therefore not
surprising to identify Co32-positive junctional complexes be-
tween adjacent hepatocytes in human clustersmaintaining cell-
to-cell communication. However, gap junction re-formation
between hepatocytes of the different species was surprising,
since it has been described that for intercellular channel for-
mation each cell should provide one hemi-channel.34
Our histological investigations identified highly differ-
entiated human liver areas within the mouse liver paren-
chyma, whereas gene expression analysis confirmed that
human cells expressed typical hepatocyte-specific functions.
Of note, a decreased gene expression was observed during
the 7-day culture period, probably as a consequence of the
isolation procedure and culture conditions. Nevertheless, the
in vivo expression levels of all analyzed human genes in-
creased to the basic levels determined in the native liver
before cell isolation, thus demonstrating the regain of the
hepatocyte-specific gene expression profile in vivo, upon
transplantation in mice.
Several methods for gene transfer into hepatocytes have
been developed, including ex vivo and in vivo approaches
using viral or nonviral vector systems leading to transient,
nearly stable or stable gene expression. The use of lentiviral
vectors has several advantages in our setup and may serve as
a proof-of-concept for the permanent genetic modification
of hepatocytes ex vivo. Within the scaffolds, hepatocytes can
be kept in culture for several days, allowing a quality check
of the gene transfer before transplantation of the cells. The
ex vivo gene transfer into purified cells allows a specific
targeting of hepatocytes and in addition avoids any dis-
semination or transduction of any unwanted cell types like
professional antigen-presenting cells, thereby helping to
evade an immune response as compared to the in vivo ap-
plication of the vectors. Since after transplantation the cells
are dividing several times, their stable modification by the
applied lentiviral vectors is a prerequisite for a sustained
transgene expression in all daughter cells after engraftment
and expansion. Recently, efficient tools for genome engi-
neering, particularly as CRISPR/Cas9, have become avail-
able providing an alternative possibility for stable genome
modifications.35 However, efficient delivery of the required
designer nucleases remains a challenge. Nonintegrating
lentiviral vectors have been suggested as an efficient de-
livery vehicle for CRISPR/Cas9.36
Altogether, this technique could be a promising option for
patients with inherited metabolic disorders because their
disease is mostly based on a single enzyme deficiency and
their liver otherwise functions normally. The finding that
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RGB marked human hepatocytes engrafted and significantly
expanded in vivo to form human clusters repopulating the
diseased mouse liver thus represents an important step to-
ward potential future therapeutic applications.
Recently, there has been a focus on deriving human he-
patocytes from other sources than human donor livers, in
particular human embryonic stem cells (ESCs) and human
induced pluripotent stem cells (iPSCs) suggesting an appli-
cation in the field of cell-based therapies and drug screen-
ing.37–47 One of the advantages is that stem cell-derived cells
may provide an unlimited supply of hepatocytes. Although
there have been improvements increasing differentiation ef-
ficiency of stem cells to functional hepatocytes, current
strategies still yield relatively heterogeneous populations.40
However, there are efforts to develop a process for the
manufacturing of iPSC master cell banks under current good
manufacturing practice and such banks became already
available.48 One of the most important challenges of these
new techniques is that tumor formation has been a concern
associated with ESC- or iPSC-based cellular therapy.37 A
recently published in vivo study applying a mouse model of
liver injury revealed that after transplantation of ESC-derived
hepatocyte-like cells all murine recipients developed large
splenic and liver tumors that contained endodermal and me-
sodermal cell types. Although such studies demonstrate that
ESC-derived cells have the potential to play an important role
in cell-based therapies, current methodologies and trans-
plantation strategies require substantial refinement before
they can be deployed safely.42 In contrast, no signs of tumor
development were detected in our applied mouse model in-
dicating that the use of primary human hepatocytes after
preculture is with lower risk for the prospective recipient. But
nevertheless, those stem cell-derived models hold great po-
tential to develop a detailed understanding of human liver
disease and metabolism including drug toxicity.44
In summary, our results demonstrate successful liver re-
population with precultured human hepatocytes indicating
that such procedures may offer new opportunities to bridge
the availability of highly differentiated hepatocytes from a
donor liver in anticipation of an appropriate recipient. Also,
the possibility to obtain human hepatocytes directly from a
patient and to transplant them back after therapeutic modifi-
cation is very encouraging. On the other hand, in the applied
mouse model, hepatic expression of the uPA transgene causes
liver damage resulting in destruction of mouse endogenous
hepatocytes and enhanced proliferation of transplanted he-
patocytes. To this regard, the model strongly resembles toxic
liver failure in humans. However, in livers of patients with
inherited metabolic disorders preparative regimen such as
partial hepatectomy might be necessary before transplanta-
tion to enhance engraftment of the transplanted spheroids.49
In conclusion, this is the first report demonstrating that
human hepatocyte spheroids obtained after 7 days preculture
and in vitro lentiviral gene transfer are able to repopulate a
recipient liver. In future, transplantation of these spheroids
into a liver-diseased recipient could present a real alterna-
tive to liver transplantation.
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